Table 1 Baseline characteristics and medication of all patients (n = 39) and healthy controls (HC, n = 19) included
From: IL-22 production of effector CD4+ T-cells is altered in SLE patients
SLE patients | HC | p value | |
|---|---|---|---|
Total number | 39 | 19 | |
Women/men | 12/1 | 18/1 | ns |
Age (years, mean ± SD) | 40 ± 14 | 36 ± 12 | ns |
SLEDAI (median, range) | 2 (0–28) | ||
Active disease (SLEDAI > 4) (n) | 7 | ||
Inactive disease (SLEDAI ≤ 4) (n) | 32 | ||
Treatment, n | |||
None | 1 | 19 | |
Glucocorticoids, n | 32 | ||
Median dose (range), dose (mg/day) | 5 (2.5–60) | ||
Immunosuppressive/immune-modulating | |||
Hydroxychloroquine, n | 17 | ||
Median dose (range), users (mg/day) | 200 (200–400) | ||
Methotrexate, n | 2 | ||
Median dose (range), users (mg/week) | 15 (15–15) | ||
Azathioprine, n | 9 | ||
Median dose (range), users (mg/day) | 125 (25–250) | ||
MMF, n | 14 | ||
Median dose (range), users (mg/day) | 1500 (360–2000) | ||
Cyclophosphamide, n | 3 | ||
Median dose (range), users (mg/day) | 200 (100–300) |